Form 4: Lifecore Biomedical CFO Ryan Lake Acquires Shares and Performance-Based Restricted Stock Units

Ryan David Lake, CFO of Lifecore Biomedical, acquired 262,500 shares of common stock and 750,000 performance-based restricted stock units on September 3, 2024.

Summary

• On September 3, 2024, Ryan David Lake, the Chief Financial Officer of Lifecore Biomedical, acquired 262,500 shares of common stock.
• Lake also acquired 750,000 performance-based restricted stock units (PRSUs) that convert into common stock on a 1-for-1 basis.
• These PRSUs vest based on Lifecore Biomedical's achievement of certain stock price milestones and expire on September 3, 2029.
• The reporting person directly owns 262,500 shares of common stock following the reported transaction.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports transactions by an insider. The acquisition of shares and PRSUs could be interpreted as a positive sign, but it's a routine disclosure.

Positives

• The acquisition of shares and performance-based restricted stock units by the CFO could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting of the performance-based restricted stock units is contingent upon the company achieving certain stock price milestones, indicating a focus on future stock performance.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions in the company's stock. This filing indicates the CFO's recent activity in Lifecore Biomedical's stock.

Comparison to Industry Standards

• Stock grants to executives are a common practice in the biotechnology and pharmaceutical industries to align management's interests with those of shareholders.
• Performance-based vesting schedules are also frequently used to incentivize executives to achieve specific company goals, such as stock price appreciation or revenue targets.
• Comparing the size of the grant to those of CFOs at comparable companies (e.g., Amphastar Pharmaceuticals, Pacira BioSciences) would provide further context.

Stakeholder Impact

• Shareholders may view the CFO's stock acquisition as a positive signal.
• The performance-based vesting of the restricted stock units aligns management's interests with shareholder value.

Key Dates